Shares of AstraZeneca fell on Monday even after the publication of positive results from a trial of its experimental vaccine COVID-19 developed in association with the University of Oxford.
The study, published in The Lancet on Monday, said healthy volunteers who received the experimental vaccine, called AZD1222, showed immune responses.
“There is still a lot of work to be done before we can confirm whether our vaccine will help control the COVID-19 pandemic, but these early results are promising,” Sarah Gilbert, an Oxford professor who heads the vaccine research, said in a statement. . Monday.
Shares in the British-Swedish pharmaceutical giant were trading higher in the early afternoon in the UK, but fell after the results were announced.
The stock rose about 5% before the announcement. It was up just 0.8% at approximately 10:20 am ET (3:20 pm UK time).
Read more: BANK OF AMERICA: Buy These 7 Pharmaceutical Shares Now As They Compete To Develop Vaccines And Treatments COVID-19
The company’s shares listed in the US were trading at $ 59.47 in early trading, down 2.7%.
Market insider information
Read more: A $ 47 billion fund manager shares 3 trades it is making upward as the economy recovers, including a play on the Tesla-led electric vehicle boom
Last week, The Daily Telegraph reported that blood samples from volunteers in the trial showed antibodies and T cells.
AstraZeneca said in June that it would supply up to 2 billion doses of the vaccine worldwide.
On Monday, Britain’s business secretary Alok Sharma said the UK had “secured early access to 90 million doses of promising coronavirus vaccines” from BioNTech / Pfizer, Valneva and AstraZeneca.
Read more: BANK OF AMERICA: Buy These 9 Stocks Prepared For Superior Performance In Any Market Environment As They Spend A Lot On Creating The Most Innovative Products
.
